Abbott’s imaging altered treatment course in 88% of artery blockages

29 June 2020 (Last Updated June 29th, 2020 10:46)

Abbott said that physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by its optical coherence tomography (OCT) imaging techniques.

Abbott’s imaging altered treatment course in 88% of artery blockages
OCT is an intracoronary imaging platform that helps to characterise and assess coronary arteries from inside the vessel with increased precision. Credit: Patho / Wiki Commons.

Abbott said that physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by its optical coherence tomography (OCT) imaging techniques.

It is based on the data generated by the LightLab Initiative, which analyses the impact of OCT imaging in the treatment of patients with vascular disease.

OCT is an intracoronary imaging platform that helps to characterise and assess coronary arteries from inside the vessel with increased precision.

It uses laser technology to capture high-resolution images inside a patient’s arteries and displays the type and severity of disease in the vessel.

Additionally, it enables the assessment of the degree and characteristics of coronary artery disease, accurate dimensional measurement of the artery and assessment of the quality of stent deployment.

LightLab initiative evaluated the role of OCT on physician decision-making, procedural efficiency and procedural safety compared to angiography during procedures for vascular disease treatment.

Data from the study indicated strong evidence of the value of using OCT for decision-making within the PCI procedure, the company noted.

According to the new data, physicians made changes in treating 31% of lesions based on OCT information after deploying a stent to treat damage to the artery previously invisible with angiography alone.

It was also revealed that physicians improved their assessment of potential blockages while using the platform.

Abbott vascular business chief medical officer and Medical Affairs divisional vice-president Nick West said: “The LightLab Initiative has given us great insights into the challenges facing interventional cardiologists in the cath lab and the impact OCT can have on the decisions physicians make in treating their patients.

“The data has also highlighted how effective OCT can be at treating patients with complex cardiovascular disease with greater precision.”